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Background: Osteoarthritis is a relatively common musculoskeletal disorder that increases in prevalence with age.
Worldwide, knee osteoarthritis is one of the leading causes of disability, particularly in the elderly. In numerous trials
of agents for long-term pain therapy, no well-established and replicable results have been achieved. Complementary
and alternative medical approaches have been employed for thousands of years to relieve knee osteoarthritis pain.
Among herbal medicines, the golden plaster is the preferred and most commonlyused method in China to reduce
pain in patients with knee osteoarthritis, as it causes few adverse effects. The purpose of this study will be to evaluate
the efficacy and safety of golden plaster on pain in patients with knee osteoarthritis.
Methods/Design: This study will be a multicenter randomized, double-blind, placebo-controlled trial. A total of 320
participants aged 45 to 79 years with knee osteoarthritis, whose scores on a visual analog scale (VAS) are more than
20 mm,will be randomly allocated into a treatment group and a control group. A golden plaster will be administered
externally to participants in the treatment group for 2 weeks, while the control group will receive a placebo plaster
externally for 2 weeks. Follow-up will be at regular intervals during a 4-week period with a VAS score for pain, quality of
life, and complications.
Discussion: This study will be a methodologically sound randomized controlled trial to assess pain relief after the
intervention of golden plaster, compared to a placebo intervention in patients with knee osteoarthritis.
Trial registration: ClinicalTrials.gov identifier: ChiCTR-TRC-13003418
Keywords: Clinical trials, Golden plaster, Knee osteoarthritis, Visual analog scaleBackground
Osteoarthritis (OA), a progressive joint disorder, is a com-
mon health issue in the aging population worldwide [1,2].
The prevalence rate of OA is 28% in people over 45 years
old and 37% in people over 65 years old [3]; thus, its
prevalence and health impact increase with age. Knee
OAis one of the leading causes of disability, particularly in
the elderly. The aim of OA treatmentisto reduce or control* Correspondence: dztang702@126.com; doctorhong@yeah.net
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reproduction in any medium, provided the orpain, improve physical function, prevent disability, and en-
hance quality of life. The non-surgical management of
OA, namely pharmacologic treatment combined with
physical therapy, is utilized more and more widely [4,5].
Pharmacologic treatments include oral analgesics, acet-
aminophen, ibuprofen, and traditional Chinese medicinal
(TCM) products [6,7]. Several systematic reviews have
outlined and showed the effectiveness of muscle strength-
ening or aerobic exercises in the osteoarthritic population
[8-11]. Acupuncture and Tuina, two kinds of the physical
therapy, have also been used for the management of OA
[6,7]. Despite numerous trials, investigators have not been
able to establish replicable relief of long-term pain.This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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employed over thousands of years to relieve knee OA
pain. Plasters are a very important therapeutic method
in TCM, inducing muscle relaxation, invigorating blood
circulation, and improving electrolyte balance and bile
release [12,13]. Among herbal medicines, the golden
plaster is the preferred and most commonly used
method in China for pain reduction in patients with
knee OA, as they cause very few adverse effects. Due to
the absence of a gold standard for the treatment of knee
OA, this trial will be conducted to detect the effective-
ness of these herbal medicines compared to a placebo-
controlled group. Therefore, we designed a randomized,
double-blind, placebo-controlled trial of golden plaster
in patients with knee OA.
Methods/Design
Study design
This clinical trial will be a multicenter, randomized,
double-blind, placebo-controlled trial. Subjects will be
enrolled at four hospitals: i) Suzhou Hospital of TCM; ii)
Longhua Hospital affiliated to Shanghai University of
TCM; iii) Zhangjiagang Hospital of TCM; and iv) Taizhou
Hospital of TCM.
The Ethics Boards of the Suzhou Hospital of TCM,
Longhua Hospital affiliated to Shanghai University of
TCM, Zhangjiagang Hospital of TCM, and Taizhou Hos-
pital of TCM have approved this study. Each participat-
ing center has obtained local Institutional Review Board
approval. All study participants will sign the written in-
formed consent before participation.
Inclusion criteria
The inclusion criteria are as follows: age 45 to 79 years;
symptomatic knee OA with a pain of at least 20 mm on
a 100-mm visual analog scale (VAS); American College
of Rheumatology criteria for symptomatic knee OA
assessed by a rheumatologist [14]; ability to read, speak,
and understand English or Chinese; and capability of un-
derstanding the study requirements and willingness to
cooperate with the study instructions.
Exclusion criteria
Exclusion criteria are as follows: psoriatic arthritis; lupus
or cancer; severe cardiac or renal impairment; significant
trauma to knees, including arthroscopy or significant in-
jury to ligaments or the menisci of the knee within one
year preceding the study; allergy to plaster.
Recruitment
Participants will be recruited through advertisements in
local newspapers, bulletin boards, and on the websites of
local medical centers. All patients will be screened ini-
tially by baseline assessment with regard to selectioncriteria before randomization. If inclusion criteria are
met and the informed consent form is signed, the pa-
tient will be sent to randomization.
Randomization
The teletherapist, a research nurse, will then register the
participant into the database for randomization. If the
participant is ready to be randomized, the teletherapist
enters “yes”; the site-specific randomization program
behind the form displays the participant’s group assign-
ment number (placebo versus golden plaster). Site-
specific randomization lists will be computer-generated
(i.e., generated by an individualized basic visual code
program) and concealed from the researchers by a senior
data manager who is not involved in the study. This in-
formation will remain confidential and is not shared
with the study sites, in accordance with the CONSORT
guidelines. This trial uses a prospective, randomized,
outcome-blinded design, in which all outcome assess-
ments are made by a research assistant blinded to treat-
ment allocation and uninvolved in patient consent and
management.
Intervention
This study will be conducted in accordance with the re-
quirements outlined in the Declaration of Helsinki, and
approved by the appropriate Institutional Review Boards.
Each participant will sign the written informed consent
form before undergoing any examination or study pro-
cedure, in compliance with Good Clinical Practice. Eli-
gible patients will be randomized into one of the two
groups: placebo and golden plaster. All drugs will be ad-
ministered externally for 2 weeks. Participants are given
in-person instructions for using the plaster by our re-
search nurses, who will be trained before this study. The
trial will be double-blind: the treating physicians, sub-
jects, investigators and statisticians are unaware of treat-
ment assignment. Randomization of subjects will occur
centrally using a random number generator. Patientvisits-
will be performed at base line, and 1-, 2-, 3-, and 4-week
follow-up after treatment (Figure 1). Assessments will be
made during all five visits. Used plasters will be reclaimed
at the 1- or 2-week follow-up visit.
The investigational group will receive one medicated
plaster, to be used twice a day (morning and evening,
approximately every 12 hours and at the same time
each day) for 14 consecutive days. The golden plaster is
a 10 × 15 cm medicated adhesive patch, composed of
Trichosanthes root, turmeric, angelica, Atractylodes, lic-
orice, rhubarb, Phellodendron, Arisaema, Magnolia bark,
tangerine peel, sesame oil, Huang Dan, and a hydrophilic
adhesive vehicle.
The control group will receive placebo plasters (con-
taining the hydrophilic adhesive vehicle only), which are
Figure 1 Study flow diagram, including recruitment, eligibility, screening, randomization, and outcome assessments.
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size, color, and odor. The tested products will be packed
and labeled, according to current Good Manufacturing
Practice and legal requirements, by the Suzhou Hospital
of TCM to ensure the participants and all personnel in-
volved in the study will remain fully blinded as to the
identity of the treatment administered. During the
process, patients will not be allowed to use other drugs.
If they do so, patients are required to provide feedback




The primary efficacy endpoint of the study will be the
VAS, which is a pain score ranging from 0 mm (no pain)to 100 mm (worst pain ever experienced) [15]. Oper-
ationally, the VAS score is usually a horizontal line,
100 mm in length, anchored by word descriptors at each
end. Patients mark the point on the line of current pain.
The VAS score is then determined by measuring in milli-
meters from the left hand end of the line to the point that
the patient marked. The VAS score will be measured
during all the assessment visits (baseline and 1-, 2-, 3-,
and 4-week follow-up).Secondary outcome measure
Health related quality of life will be measured using the
SF-36 questionnaire [16]. The SF-36 questionnaire is a
widely used measure of general health status, consisting
of eight parts: physical functioning, role-physical, bodily
Liu et al. Trials 2013, 14:383 Page 4 of 5
http://www.trialsjournal.com/content/14/1/383pain, general health, vitality, social functioning, role-
emotional, and mental health.
Safety assessments
All subjects are to be questioned about adverse events
during the treatment at each visit, and all adverse events
reported will be analyzed, regardless of the investigators’
assessments of causality. Safety will be assessed by complete
blood cell count, erythrocyte sedimentation rate, blood
chemistry, and urinalysis.
Sample size
We will estimate the required sample size for this trial
based on the following calculation: n = 2σ2 × f(α, β)/(μ1-μ2)2
[17]. First, we estimate that an absolute improvement of
4.7 (from μ1 to μ2) in VAS score is likely the smallest
clinically-relevant difference for patients with OA. Second,
we assume that standard deviation of VAS score may be
2.9 (σ = 2.9) at baseline [18]. Based on these assumptions,
we will require 84 patients in each group to have at least a
90% power (β = 0.1) and to rule out a two-sided type I
error of 5% (α = 0.05). The number of patients actually
provides less than 80% power, assuming a withdrawal rate
of 20%. Therefore, we will recruit a total of 320 patients,
160 patients in each group.
Statistical analysis
The data will be collected and analyzed according to the
intention-to-treat principle. Standard statistical tech-
niques will be used to describe characteristics of patients
in both groups. We will compare baseline characteristics
in both groups and, if incomparability appears, we will
perform a secondary analysis, adjusting for differences.
The primary outcome will be compared between both
groups using analysis of variance for repeated measures.
All statistical analyses will be performed using SAS ver-
sion 9.1 or a later version. All statistical tests will be
two-sided and the level of significance will be set at 0.05.
The last-observation-carried-forward method will be
used to input data with dropouts. Continuous variables
will be expressed as mean ± SD, and categorical variables
as number and percentage [19]. If adjustment for possible
baseline incomparability is needed, analysis of covariance
will be performed [20].
Discussion
Despite considerable study, there is no generally effective
treatment for patients who suffer from OA. In some
contexts, various complementary and alternative medical
treatments have been administered for OA in clinical
practices [8,10,21]. Some studies have reported the effect-
iveness of herbal medicine, which is the most popular
form of complementary and alternative medical therapy
for the treatment of OA, either used alone or concomi-tantly with usual care [6,22-26]. The quality and small
sample sizes of the few trials that have been conducted
have made it difficult to reach firm conclusions about
these treatments. Well-designed randomized controlled
trials are needed to examine the efficacy of TCM treat-
ments for OA. The biggest advantage of the present trial
is an external placebo control. The purpose of this study
will be to evaluate the basic clinical efficacy and safety data
for the golden plaster in the treatment of patients with
knee OA.
Trial status
Patient recruitment for the trial will start from the end
of 2013. Data collection will finish at the end of 2015.
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